CoChat

Optimized use of the FilmArray Meningitis/Encephalitis panel for early discontinuation of antibiotic therapy

Open access

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index; 18 of the 29 sources its claims cite were checked for support.

Abstract

Suspected meningitis/encephalitis cases require prompt empirical antimicrobial therapy. Syndromic diagnostics like the FilmArray Meningitis/Encephalitis (FAME) panel offer rapid results and are increasingly used despite high costs. This study assessed FAME's integration in clinical microbiology laboratories' everyday practice and its impact on early treatment decisions. The FilmArray Meningitis/encephalitis panel Outcome Study (FAMOuS) retrospectively reviewed biological data, treatments before/after FAME, and outcomes from 783 patients across six French hospitals over a 3-year period. FAME results were 80% negative, 7% bacterial, and 13% viral, with no bacterial false negatives. Positive results in samples with <10 leukocytes were exclusively seen in immunocompromised individuals and children under 2. Positive results prompted therapeutic changes in 74% of cases, compared to 50% for negatives. FAMOuS enabled the proposal of a decision-support flowchart to optimize the rational use of FAME and support antibiotic stewardship, with the potential to increase early antibiotic discontinuation and reduce unnecessary testing.IMPORTANCEPrompt identification of infectious causes is essential in suspected meningitis and encephalitis, where timely treatment decisions can be lifesaving. The FAMOuS study evaluated the use of the FilmArray Meningitis/Encephalitis (FAME) panel across six French hospitals, analyzing nearly 800 patient episodes. The findings demonstrate that FAME offers reliable results that directly influence clinical management-guiding therapeutic adjustments in most positive cases and supporting early antibiotic discontinuation when appropriate. The study highlights specific patient contexts where FAME provides the greatest clinical value and proposes a decision-support flowchart to optimize its rational use. By integrating rapid molecular diagnostics into everyday practice, this work contributes to improved patient care and reinforces hospital antibiotic stewardship strategies.

Overview

CoChat Summary

## TL;DR

This retrospective multicenter study of 783 patients across six French hospitals found that the FilmArray Meningitis/Encephalitis (FAME) panel was mostly negative (80%) and could support early antimicrobial de-escalation, especially when combined with CSF WBC and lactate results. The authors propose a flowchart to target testing and improve antibiotic stewardship, but note that prospective validation is still needed.

## Key findings

  • Among 786 patients tested, 3 invalid tests were excluded; of the 783 evaluable samples, FAME was 80% negative, 7% bacterial positive (n = 55), 13% viral positive (n = 100), and 1 sample positive for Cryptococcus.
  • No bacterial false negatives were reported in the abstract; in the results, one negative FAME corresponded to an H. influenzae culture considered laboratory contamination, while 10 true meningitis cases were FAME-positive but culture-negative.
  • CSF markers were strongly associated with bacterial FAME positivity: bacterial cases had median CSF WBC 1,530 vs 135 in viral and 17 in negative cases, and median CSF lactate 11.6 mmol/L vs 2.3 and 2.4 mmol/L.
  • In treated patients with negative direct examination, a negative FAME led to de-escalation in 25% and no impact in 71%; after excluding untreated patients, de-escalation rose to 50% for negative FAME and 74% overall for positive FAME results.
  • CSF lactate ROC analysis identified an optimal bacterial-infection cutoff of 6.6 mmol/L; the authors state that <3.2 mmol/L supports early antibiotic discontinuation when FAME is negative.

## Methods

  • Retrospective multicenter cohort (FAMOuS) of patients of any age from six French tertiary hospitals who underwent FAME on lumbar puncture between January 2019 and December 2022.
  • Collected data included demographics, hospitalization unit, immunodepression status, CSF biochemistry and microbiology, FAME result, dexamethasone use, hospital-acquired vs community-acquired status, targeted antibiotics/antivirals before and within 24 h after FAME, length of stay, and 30-day death.
  • Analysis used descriptive statistics, group comparisons (χ²/Fisher, t-test/Mann–Whitney), and univariate/multivariate conditional logistic regression to identify correlates of FAME positivity; ROC analysis was used for CSF lactate thresholds.

## Limitations

  • The paper explicitly states limitations: retrospective design, heterogeneity of inclusion across centers, incomplete lactate measurements in some patients, and lack of independent adjudication of therapeutic decisions.
  • Evident from the text: clinical symptoms such as headache, fever, photophobia, phonophobia, and neck stiffness were not collected, so clinical presentation could not be directly analyzed.
  • Evident from the text: the proposed flowchart was not prospectively validated, and the authors call for independent prospective evaluation.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1128/spectrum.00566-26

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig 1 Overview of FAME results across departments and acquisition settings. (A) Distribution according to acquisition type. (B) Distribution of FAME according to departments. The percentages of negative results are indicated for each department.
Fig 1 Overview of FAME results across departments and acquisition settings. (A) Distribution according to acquisition type. (B) Distribution of FAME according to departments. The percentages of negative results are indicated for each department.CC BY · PubMed Central
Fig 2 Forest plots of main factors associated with FAME positive results. CSF, cerebrospinal fluid; FAME, FilmArray Meningitis/Encephalitis panel; RBC, red blood cells; WBC, white blood cells.
Fig 2 Forest plots of main factors associated with FAME positive results. CSF, cerebrospinal fluid; FAME, FilmArray Meningitis/Encephalitis panel; RBC, red blood cells; WBC, white blood cells.CC BY · PubMed Central
Fig 3 FAME result impact on antibiotic therapy. (A) All patients. (B) Patients with antibiotic therapy administered either before or after the FAME results. (C) Sankey diagram of antibiotic treatment evolution between before and after FAME.
Fig 3 FAME result impact on antibiotic therapy. (A) All patients. (B) Patients with antibiotic therapy administered either before or after the FAME results. (C) Sankey diagram of antibiotic treatment evolution between before and after FAME.CC BY · PubMed Central
Fig 4 Flowchart management of meningitis/encephalitis suspicion.
Fig 4 Flowchart management of meningitis/encephalitis suspicion.CC BY · PubMed Central

Verification

Claims the paper makes

10 Valid · 1 Not valid · 3 Not checked · 47 Own results and interpretations

21 more claims

Create a free account to see all 61 claims and every source verdict.

See all claims — free account
  • Probably not a substantial claim. 10
  • It may state two separate claims as one. 27

Create a free account to see these claims.

Citations

Cites

Cited by

See all 1

Metadata

Authors
Nicolau-Guillaumet, N., Moutel, M., Plouzeau-Jayle, C., Pean de Ponfilly, G., Courbin, V., Ranc, A.-G., Revillet, H., Mourvillier, B., Hentzien, M., Muggeo, A., Guillard, T., & On behalf of the GMC Study Group
Affiliations
  • Inserm (FR)
  • Centre Hospitalier Universitaire de Reims (FR)
  • Centre Hospitalier Universitaire de Poitiers (FR)
  • Service de Microbiologie Clinique, Hôpitaux Paris Saint-Joseph and Marie-Lannelongue
  • Hôpital d'Instruction des Armées Bégin (FR)
  • Hospices Civils de Lyon (FR)
  • Service de Bactériologie-Hygiène Hospitalière, CHU de Toulouse, Hôpital Purpan, Institut de Recherche en Santé Digestive (IRSD), Université de Toulouse, INSERM, INRAE, ENVT, UPS
Corresponding author
Guillard, Thomas
Venue
Microbiology Spectrum
Published
2026-06-02
Volume
14
Issue
6
Pages
e0056626-e0056626
ISSN
2165-0497 (ISSN-L)
OpenAlex
W7160383516
Cited by
1
References
29
Citations by year
2026: 1
FWCI
4.60
Type
journal article
Language
en
Open access
Licence
Locations
  • Microbiology Spectrum (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by)
  • HAL (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Microbiology (medical) › Bacterial Identification and Susceptibility Testing
  • Life Sciences › Immunology and Microbiology › Microbiology › Bacterial Infections and Vaccines
  • Health Sciences › Medicine › Infectious Diseases › Infectious Encephalopathies and Encephalitis
Keywords
FilmArray Meningitis/Encephalitis panel, meningitis, encephalitis, antibiotic stewardship, molecular diagnosis, empirical antimicrobial therapy, decision support, immunocompromised patients, children, unnecessary testing
MeSH terms
Antimicrobial Stewardship, Anti-Bacterial Agents, Child, Child, Preschool, Encephalitis, Female, France, Humans, Infant, Male, Meningitis, Retrospective Studies, Molecular Diagnostic Techniques

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.